Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-LIFE long-term follow-up after SELECT trial
jRCT1031230250Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Open-label, single-arm trial of semaglutide in Overweight, obesity, cardiac morbidity and 1 more, sponsored by Novo Nordisk. Primary endpoints: All-cause mortality, Myocardial infarction and 10 more. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
Overweightobesitycardiac morbiditytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1031230250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031230250.